Yang Qiu

1.1k total citations
43 papers, 809 citations indexed

About

Yang Qiu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yang Qiu has authored 43 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yang Qiu's work include Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (7 papers) and Metabolism, Diabetes, and Cancer (5 papers). Yang Qiu is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (7 papers) and Metabolism, Diabetes, and Cancer (5 papers). Yang Qiu collaborates with scholars based in China, United States and Japan. Yang Qiu's co-authors include Terence E. Ryan, Vivian Zhang, Lei Zhu, James X. Rong, Jay C. Strum, Michael K. Hansen, Yuji Okamoto, Michael Mattie, S Asano and Hiroyuki Higashiyama and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and PLoS ONE.

In The Last Decade

Yang Qiu

42 papers receiving 797 citations

Peers

Yang Qiu
Masayoshi Suda Japan
Yun Kyung Lee South Korea
Wenliang Zha China
Qiuyan Wu China
Yuchen Ge China
Jani Saksi Finland
Wataru Mizushima Japan
Junping Hu China
Anqi Ge China
Manling Liu China
Masayoshi Suda Japan
Yang Qiu
Citations per year, relative to Yang Qiu Yang Qiu (= 1×) peers Masayoshi Suda

Countries citing papers authored by Yang Qiu

Since Specialization
Citations

This map shows the geographic impact of Yang Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang Qiu more than expected).

Fields of papers citing papers by Yang Qiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang Qiu. The network helps show where Yang Qiu may publish in the future.

Co-authorship network of co-authors of Yang Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Yang Qiu. A scholar is included among the top collaborators of Yang Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang Qiu. Yang Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Yu-Ting, Yu‐Zhong Yu, Tao Xie, et al.. (2025). TGFβ-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt/β-catenin signaling pathway. Drug Resistance Updates. 81. 101227–101227. 2 indexed citations
2.
Li, Junfang, et al.. (2025). Integrated analyses of prognostic and immunotherapeutic significance of EZH2 in uveal melanoma. Methods. 234. 242–252. 2 indexed citations
3.
Lin, Shengchao, Yu Zhang, Jun Yao, et al.. (2024). DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. Journal of Translational Medicine. 22(1). 766–766. 9 indexed citations
4.
O’Shaughnessy, Joyce, P. Schmid, Zhimin Shao, et al.. (2024). 436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer. Annals of Oncology. 35. S403–S403. 1 indexed citations
5.
Yao, Jun, Qu Chen, Bing Li, et al.. (2024). DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. Journal of Translational Medicine. 22(1). 362–362. 7 indexed citations
6.
7.
Raghav, Kanwal, Takayuki Yoshino, Hiroya Taniguchi, et al.. (2021). P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer. Annals of Oncology. 32. S111–S111.
8.
Yu, Helena A., Christina S. Baik, Kathryn A. Gold, et al.. (2020). LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC. Annals of Oncology. 31. S1189–S1190. 16 indexed citations
9.
Qiu, Yang, et al.. (2020). Associations between the levels of thyroid hormones and abdominal obesity in euthyroid post-menopausal women. Endokrynologia Polska. 71(4). 299–305. 9 indexed citations
10.
11.
Ning, Xiaomin, Shuai Liu, Yang Qiu, et al.. (2016). Expression Profiles and Biological Roles of miR-196a in Swine. Genes. 7(2). 5–5. 13 indexed citations
12.
Tang, Lizhi, Qingguo Lü, Hongyi Cao, Yang Qiu, & Nanwei Tong. (2016). PPARD rs2016520 polymorphism is associated with metabolic traits in a large population of Chinese adults. Gene. 585(2). 191–195. 12 indexed citations
13.
14.
Tang, Lei, YuYe J. Tong, Haixia Cao, et al.. (2014). The MTMR9 rs2293855 polymorphism is associated with glucose tolerance, insulin secretion, insulin sensitivity and increased risk of prediabetes. Gene. 546(2). 150–155. 7 indexed citations
15.
Qiu, Yang, Hongyi Cao, Yuzhen Tong, et al.. (2013). Associations of the PTEN −9C>G polymorphism with insulin sensitivity and central obesity in Chinese. Gene. 527(2). 545–552. 2 indexed citations
16.
Yang, Yan, Yuzhen Tong, Meng Gong, et al.. (2013). Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor. Cellular Signalling. 26(2). 268–278. 35 indexed citations
17.
Qiu, Yang, Tomoko Tanaka, Hajime Nawata, & Toshihiko Yanase. (2012). Dihydrotestosterone Inhibits Lectin-Like Oxidized-LDL Receptor-1 Expression in Aortic Endothelial Cells via a NF-κB/AP-1-Mediated Mechanism. Endocrinology. 153(7). 3405–3415. 7 indexed citations
18.
Cheng, Senping, Jianfeng Chen, Yang Qiu, et al.. (2006). Carbaryl inhibits basal and FSH-induced progesterone biosynthesis of primary human granulosa-lutein cells. Toxicology. 220(1). 37–45. 16 indexed citations
19.
Qiu, Yang, et al.. (2006). Cancer: A medical emergency. Medical Hypotheses. 67(5). 1054–1059. 28 indexed citations
20.
Hurban, Patrick, et al.. (2003). The auxin-induced transcriptome for etiolated Arabidopsis seedlings using a structure/function approach. Functional & Integrative Genomics. 3(4). 135–143. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayoshi Suda Breakdown of academic impact, for papers by Yun Kyung Lee Breakdown of academic impact, for papers by Wenliang Zha Breakdown of academic impact, for papers by Qiuyan Wu Breakdown of academic impact, for papers by Yuchen Ge Breakdown of academic impact, for papers by Jani Saksi Breakdown of academic impact, for papers by Wataru Mizushima Breakdown of academic impact, for papers by Junping Hu Breakdown of academic impact, for papers by Anqi Ge Breakdown of academic impact, for papers by Manling Liu
Rankless by CCL
2026